Tweet
J Physiol
. 2020 Jul 25.
doi: 10.1113/JP280138. Online ahead of print.
Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019
Natthaphat Siri-Angkul 1 2 3 , Siriporn C Chattipakorn 1 2 , Nipon Chattipakorn 1 2 3
Affiliations
- PMID: 32710575
- DOI: 10.1113/JP280138
Abstract
The coronavirus disease 2019 (COVID-19) is the third major coronavirus outbreak of this century. Its etiologic agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are speculated to potentiate SARS-CoV-2 infectivity and worsen COVID-19 disease progression by altering ACE2 expression. Current evidence of ACEI/ARB-ACE2 interaction as well as the effects of ACEIs/ARBs on viral-associated acute lung injury is summarized and discussed in this mini-review. Critical questions of translational importance that need to be addressed by further investigations are also presented. This article is protected by copyright. All rights reserved.
Keywords: ACE2; ACEI; ARB; COVID-19; SARS-CoV-2.